Skip to main content
Emcure Pharmaceuticals Limited logo

Emcure Pharmaceuticals Limited — Investor Relations & Filings

Ticker · EMCURE ISIN · INE168P01015 LEI · 335800WYB6OIBY9EOZ42 BSE.NS Manufacturing
Open in API
Filings indexed 198 across all filing types
Latest filing 2026-05-20 Regulatory Filings
Country IN India
Listing BSE.NS EMCURE

About Emcure Pharmaceuticals Limited

https://www.emcure.com

Emcure Pharmaceuticals Limited is a research-driven global pharmaceutical organization engaged in the development, manufacturing, and marketing of a broad range of differentiated pharmaceutical products. The company maintains a diverse portfolio across several key therapeutic areas, including gynaecology, cardiovascular, oncology, anti-infectives, and HIV/AIDS. With a strong emphasis on research and development, Emcure operates multiple state-of-the-art manufacturing facilities and R&D centers globally. Its business model focuses on complex generics and innovative formulations, serving healthcare needs in over 70 countries. The company is recognized for its vertically integrated operations and commitment to high-quality standards, catering to both regulated and emerging markets worldwide.

Recent filings

Filing Released Lang Actions
Intimation of schedule of Analyst/ Investor Meeting on June 09, 2026
Regulatory Filings Classification · 85% confidence The document is an SEBI (Listing Obligations and Disclosure Requirements) Regulation 30 intimation to stock exchanges disclosing the schedule of analyst/investor meetings. It does not contain financial results, presentations, or actual report content, nor does it announce voting results, capital changes, or dividends. This is a routine regulatory disclosure under listing rules, making it a general regulatory filing.
2026-05-20 English
Intimation of schedule of Analyst/ Investor Meeting on June 01, 2026
Regulatory Filings Classification · 81% confidence The document is an exchange intimation under SEBI LODR Regulation 30, notifying the schedule of analyst/investor meetings. It does not present financial results, reports, or detailed investor presentations, nor does it amend capital structure or governance. It is a regulatory announcement, fitting the fallback category for miscellaneous filings (Regulatory Filings).
2026-05-20 English
Intimation of schedule of Analyst/ Investor Meeting on May 27, 2026
Regulatory Filings Classification · 88% confidence The document is a SEBI LODR regulatory filing notifying exchanges of the schedule for analyst/investor meetings. It does not contain financial statements, a presentation deck, or declare dividends, nor is it an AGM notice or earnings release. It is a general regulatory announcement under Listing Obligations and Disclosure Requirements, fitting the fallback category Regulatory Filings (RNS).
2026-05-20 English
Intimation of schedule of Analyst/ Investor Meeting on May 26, 2026
Regulatory Filings Classification · 80% confidence The document is a short SEBI Regulation 30 intimation announcing the schedule of analyst/investor meetings. It does not contain financial results, presentations, or substantive report content. It is a routine regulatory disclosure notice and therefore falls into the general Regulatory Filings category (RNS).
2026-05-20 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 85% confidence The document is a formal stock-exchange filing notifying the National Stock Exchange of India and the BSE of the Company’s upcoming Analyst/Investor meeting schedule pursuant to SEBI LODR Regulations. It does not contain any financial results, report data, presentation materials, or substantive auditor or governance information. Instead, it is a routine regulatory disclosure of upcoming events, fitting the fallback category for miscellaneous compliance announcements: Regulatory Filings (RNS).
2026-05-20 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 90% confidence The document is a formal notice to stock exchanges under SEBI LODR Regulation 30, providing the schedule of analyst/investor meetings. It does not contain financial results, capital changes, or an actual investor presentation, but is a regulatory disclosure. This fits the catch-all ‘Regulatory Filings’ category for miscellaneous exchange filings rather than a specific report type.
2026-05-20 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.